Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology using a proprietary discovery engine platform.
Ryvu Therapeutics
TAP Partner
Krakow,
Poland
Project Title
A phase 2 study of RVU120, a novel CDK8 inhibitor, in patients with low-risk MDS A phase 2 study of RVU120, a novel CDK8 inhibitor, in patients with myelofibrosis A phase 2 study of RVU120, a novel CDK8 inhibitor, in combination with venetoclax in patients with AML
Program
Therapy Acceleration Program